| Literature DB >> 33230062 |
Ping-Hsing Tsai1, Wei-Yi Lai1, Yi-Ying Lin1, Yung-Hung Luo2,3, Yi-Tsung Lin3,4, Hsiao-Kang Chen3,5, Yuh-Min Chen2,3, Yi-Chun Lai3,5, Li-Chiao Kuo3,5, Shew-Dan Chen3,5, Kao-Jung Chang1,3, Cheng-Hsuan Liu1,3, Shih-Chieh Chang3,5, Fu-Der Wang3,4, Yi-Ping Yang1,3,6.
Abstract
Coronavirus disease 2019 (COVID-19) is mainly an infectious disease of the respiratory system transmitted through air droplets, and pulmonary symptoms constitute main presentations of this disease. However, COVID-19 demonstrates a clinically diverse manifestation ranging from asymptomatic presentation to critically illness with severe pneumonia, acute respiratory distress syndrome, respiratory failure, or multiple organ failure. Accumulating evidences demonstrated that COVID-19 has extrapulmonary involvement, including neurological, smelling sensation, cardiovascular, digestive, hepatobiliary, renal, endocrinologic, dermatologic system, and others. Over a third of COVID-19 patients manifest a wide range of neurological symptoms involving the central/peripheral nervous system. Underlying cardiovascular comorbidities were associated with detrimental outcomes, meanwhile the occurrence of cardiovascular complications correlate to poor survival. Gastrointestinal symptoms frequently occur and have been associated with a longer period of illness. Impaired hepatic functions were associated with the severity of the disease. Higher rate of acute kidney injury was reported in critically ill patients with COVID-19. Endocrinologic presentations of COVID-19 include exacerbating hyperglycemia, euglycemic ketosis, and diabetic ketoacidosis. The most common cutaneous manifestation was acro-cutaneous (pernio or chilblain-like) lesions, and other skin lesions consist of maculopapular rash, vesicular lesions, livedoid/necrotic lesions, exanthematous rashes, and petechiae. This review article summarized the general clinical signs and symptoms, radiologic features, and disease manifestation with progression in patients with COVID-19.Entities:
Mesh:
Year: 2021 PMID: 33230062 DOI: 10.1097/JCMA.0000000000000463
Source DB: PubMed Journal: J Chin Med Assoc ISSN: 1726-4901 Impact factor: 2.743